A comparison of two methods to prevent cardiac muscle damage during cardiopulmonary bypass surgery

Investigation of the changes in cardiac muscle damage marker and serum lactate in pateints undergoing cardiopumonary bypass using the del Nido cardioplegia versus Custodiol: A pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017083035991N1

Enrollment

Registered

2017-10-25

Start date

2017-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery bypass graft surgery. Unspecified complication of cardiac and vascular prosthetic device, implant and graft

Interventions

Intervention 1: del Nido cardioplegia. Intervention 2: Custodial cardioplegia.

Treatment - Surgery

del Nido cardioplegia

Custodial cardioplegia

Eligibility

Sex/Gender

All

Age

No minimum to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients undegoing coronary artery bypass and valve graft surgery, informed satisfaction. Exclusion criteria: diagnosed inflammatory diseases before surgery, acute myocardial infarction, patient dissatisfaction, dialysis-requiring renal failure, ejection fraction less than 15%, second surgery, emergency patients, predictive pulmonary disease patients, cardiomyopathy patients.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cardiac Troponin I. Timepoint: Before operation, after operation and 24 hours after operation. Method of measurement: ng/ml using enzyme immunoassay.;Serum Lactate. Timepoint: Prior to the Coronary artery bypass graft surgery, Immediate post aortic declamping, At the entrance to the ICU, 6, 12, and 24 hours post entrance to the ICU. Method of measurement: Biochemical analyzer.	—

Secondary

Measure	Time frame
Hemoglobin. Timepoint: Before operation, after operation and 24 hours after operation. Method of measurement: Hematology analyzer.;Hematocrit. Timepoint: Before operation, after operation and 24 hours after operation. Method of measurement: Hematology analyzer.;Platelet count. Timepoint: Before operation, after operation and 24 hours after operation. Method of measurement: Hematology analyzer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Javad Mehranbaniyan

Tehran Heart Center

mehrabanian56@gmail.com+218 8029203

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026